Top Anti Cancer Imported Medicine Drugs in India - Pharama Five
Help Desk :+916374297988

Pharma Five is a registered firm based in India. We specialize in Named Patient Imports, Imported cancer drugs, Imported medicines in india.

Contact Us Pharma Five Door No. 74, Old No. 26, Fagun Mansion, 3rd Floor, Ethiraj Salai, Egmore, Chennai - 600008 +916374297988 info@pharmafive.org

Best Hyrnuo (Sevabertinib) Medicine in India

Buy Hyrnuo (Sevabertinib) Medicine in India

Hyrnuo (Sevabertinib)

Medicine name : Hyrnuo

Generic name : Sevabertinib

Manufactured By : Bayer Healthcare Pharmaceuticals Inc

Indications : Locally advanced/metastatic non-squamous NSCLC, HER2(ERBB2) TKD activating mutations - expanded to 1st-line setting

Medicine Description : A targeted therapy for HER2 (ERBB2) mutation-positive non-small cell lung cancer (NSCLC), Hyrnuo (Sevabertinib) blocks abnormal HER2 tyrosine kinase activity to help slow cancer cell growth. It is used in adults with locally advanced or metastatic non-squamous NSCLC with activating HER2 TKD mutations, including eligible patients in the first-line setting. Taken orally, it provides targeted treatment for HER2-mutated lung cancer. Monitoring is important to manage potential treatment-related adverse effects.

Product Introduction

Hyrnuo (Sevabertinib) is a targeted anticancer treatment used for adults with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) with activating HER2 (ERBB2) tyrosine kinase domain (TKD) mutations. It works by blocking abnormal HER2 signaling that contributes to cancer-cell growth and survival, helping to slow tumor growth and disease progression.

Hyrnuo (Sevabertinib) is taken orally as directed by your doctor and should be used consistently according to the prescribed treatment schedule. Regular medical check-ups and laboratory tests may be required to monitor treatment response, liver function, and other aspects of your health during treatment.

Common side effects of Hyrnuo (Sevabertinib) may include diarrhea, rash, nail changes, mouth sores, nausea, decreased appetite, fatigue, muscle or joint pain, dry skin, and increased liver enzymes. Serious treatment-related effects may also occur, including lung, liver, eye, or pancreatic problems. Inform your doctor promptly if you develop breathing difficulties, persistent cough, severe diarrhea, vision changes, or other concerning symptoms.

Uses Of Hyrnuo (Sevabertinib)

Treatment of HER2-Mutated Non-Small Cell Lung Cancer

Benefits Of Hyrnuo

Hyrnuo (Sevabertinib) provides targeted treatment for adults with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) with activating HER2 (ERBB2) tyrosine kinase domain mutations. By blocking abnormal HER2 signaling, it helps inhibit cancer-cell growth and survival, slow disease progression, and provide a targeted treatment option for eligible patients, including those receiving first-line therapy.

Side Effects Of Hyrnuo (Sevabertinib)

Some side effects of Hyrnuo (Sevabertinib) may improve as the body adjusts to the treatment. Consult your doctor if any side effect persists, becomes severe, or causes concern.

Common Side Effects of Hyrnuo (Sevabertinib)

  • Diarrhea
  • Rash
  • Nail changes
  • Mouth sores
  • Nausea
  • Decreased appetite
  • Fatigue
  • Muscle or joint pain
  • Dry skin
  • Increased liver enzymes
How To Use Hyrnuo

Take Hyrnuo (Sevabertinib) exactly as prescribed by your doctor. It is taken orally with food, usually at approximately the same time each day. Swallow it whole with water and do not crush, chew, or break it. Follow your doctor's instructions if you miss a dose or vomit after taking it. Attend regular medical check-ups and laboratory tests to monitor your response to treatment and possible side effects.

How Hyrnuo (Sevabertinib) Works

Hyrnuo (Sevabertinib) is a HER2 tyrosine kinase inhibitor that targets activating HER2 (ERBB2) tyrosine kinase domain mutations in cancer cells. It blocks abnormal HER2 signaling involved in cancer-cell growth and survival, helping to inhibit tumor growth and slow the progression of HER2-mutated non-small cell lung cancer.

Safety Advice

AlcoholCONSULT YOUR DOCTOR

Limit or avoid alcohol during treatment, as it may worsen side effects such as nausea, fatigue, or dizziness. Follow your doctor's advice.

PregnancyCONSULT YOUR DOCTOR

Hyrnuo may harm an unborn baby. Women who can become pregnant should use effective contraception during treatment and for the recommended period after the last dose.

BreastfeedingCONSULT YOUR DOCTOR

Do not breastfeed during treatment and for the recommended period after the last dose, as the effects on a breastfed child are not fully known.

DrivingCONSULT YOUR DOCTOR

Avoid driving or operating machinery if you experience fatigue, dizziness, vision changes, or other effects that may impair your alertness.

KidneyCAUTION

Inform your doctor if you have kidney problems. Your doctor may monitor kidney function and provide appropriate medical care during treatment.

LiverCAUTION

Tell your doctor about any liver condition. Regular liver function tests may be required, and report yellowing of the skin or eyes, dark urine, or unusual tiredness promptly.

Quick Tips
  • Take Hyrnuo (Sevabertinib) exactly as prescribed and follow your doctor's treatment schedule carefully.
  • Take it with food at approximately the same time each day for consistent treatment.
  • Report new or worsening cough, breathing difficulties, or chest discomfort promptly.
  • Inform your doctor if severe diarrhea, mouth sores, skin or nail changes, or vision problems develop.
  • Attend regular medical check-ups and laboratory tests to monitor liver function and other treatment-related effects.
  • Read More About - Hyrnuo (Sevabertinib) from Pharma Five.
Faq

General Question

Hyrnuo (Sevabertinib) is an oral targeted therapy used to treat adults with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) with activating HER2 (ERBB2) tyrosine kinase domain (TKD) mutations.

Hyrnuo works by inhibiting abnormal HER2 tyrosine kinase activity caused by activating HER2 mutations. This helps block cancer-promoting signals and slow the growth and spread of tumor cells.

Hyrnuo is intended for adults with locally advanced or metastatic non-squamous NSCLC whose tumors have activating HER2 (ERBB2) TKD mutations. It should be used only under the supervision of an oncologist.

Hyrnuo is taken orally as prescribed by the treating doctor. The recommended dose and duration depend on the patient's condition and treatment plan. Follow the prescribed schedule carefully and do not change the dose without medical advice.

Common side effects may include diarrhea, nausea, vomiting, fatigue, decreased appetite, rash, muscle or joint pain, headache, abdominal discomfort, and changes in liver function tests.

Hyrnuo may cause serious side effects in some patients. These can include lung-related problems, liver toxicity, heart-related effects, and other significant reactions. Contact your doctor promptly if you develop severe breathing problems, persistent cough, yellowing of the skin or eyes, chest discomfort, or other concerning symptoms.

The duration of Hyrnuo treatment varies from patient to patient. Treatment is generally continued as directed by the oncologist while the medicine is providing benefit and side effects remain manageable. Do not stop treatment without consulting your doctor.

It is advisable to limit or avoid alcohol while taking Hyrnuo because alcohol may increase the risk of certain side effects, particularly those affecting the liver. Discuss alcohol consumption with your doctor before drinking.

Hyrnuo may harm an unborn baby and should generally be avoided during pregnancy unless specifically prescribed by a doctor. Women who can become pregnant should use effective contraception during treatment and follow their doctor's advice regarding contraception after treatment.

Yes. Hyrnuo may interact with certain medicines, including drugs that affect liver enzymes and medicines that can influence heart rhythm or other treatment-related risks. Inform your doctor about all prescription medicines, over-the-counter medicines, vitamins, and herbal supplements you are taking.

If you miss a dose of Hyrnuo, take it as soon as you remember according to your doctor's instructions. If it is close to the next scheduled dose, follow your prescribed missed-dose instructions and do not take an extra dose to make up for the missed one.

Hyrnuo can be taken orally according to the instructions provided by your doctor. Follow the prescribing instructions regarding food and maintain the same administration routine each day unless your healthcare provider advises otherwise.

Tell your doctor about any existing medical conditions and all medicines you use before starting Hyrnuo. Regular monitoring may be required for liver function and other potential treatment-related effects. Seek medical attention for severe breathing difficulties, significant weakness, jaundice, or other unusual symptoms.

Store Hyrnuo according to the storage instructions provided on the product packaging or by your pharmacist. Keep it in its original container, away from excessive heat and moisture, and out of reach of children. Do not use the medicine after its expiry date.

Hyrnuo should be obtained through a licensed pharmacy or authorized medicine supplier and used only with a valid prescription from a qualified healthcare professional. Pharma Five assists in its procurement.